Exelixis | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Bayer EUR 110.85B 3.9B 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Cytokinetics USD 1.4B 34.39M 2024-12
Eisai JPY 1.43T 111.45B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Genmab DKK 45.81B 6.15B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Incyte USD 5.44B 431.89M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
MacroGenics USD 261.65M 2.84M 2024-12
Merck USD 117.11B 426M 2024-12
Moderna USD 14.14B 1.66B 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Sanofi 132.8B 3.04B 2024-12
Takeda JPY 15.11T 533.85B 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Xencor USD 951.94M 31.69M 2024-12



Exelixis Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.